The weight‑loss drug divide: Private prescribing is lowest where need is greatest

Wegovy and Mounjaro, two recently approved injectable medications that can produce significant weight loss, are being prescribed at markedly lower rates in England’s most obese communities, according to data from a private healthcare provider. The study, which analysed prescription patterns across 1,200 GP practices, found that areas with the highest obesity prevalence received fewer prescriptions than regions with lower rates of overweight and obesity.

The provider’s database shows that only 4 % of eligible patients in high‑obesity districts were prescribed either drug, compared with 12 % in lower‑obesity areas. The discrepancy coincides with the fact that both medications are not yet fully funded by the National Health Service, making them costly for private patients. In addition, the study noted limited awareness among primary‑care clinicians in deprived neighbourhoods and a shortage of specialist weight‑management services that could facilitate prescribing.

The findings raise concerns about equitable access to emerging obesity treatments. If the trend continues, patients in the communities most in need of effective weight‑loss options may remain underserved. Policymakers and health‑care providers are urged to examine barriers to prescription and to consider strategies that ensure broader, more inclusive uptake of these therapies.